Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Spagnolo

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
Oncotargets and Therapy|February 6, 2015
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategiesFrancesco Spagnolo, Paola Ghiorzo, Laura Orgiano, et al.
Frontiers in Oncology|September 13, 2021
Immunotherapy for the Treatment of Cutaneous Squamous Cell CarcinomaAndrea Boutros, Federica Cecchi, Enrica Teresa Tanda, et al.
Journal for Immunotherapy of Cancer|May 27, 2026
Immunotherapy for early-stage cutaneous squamous cell carcinomaAndrea Boutros, Yu-Ju Kuo, Alexander Maxwell Menzies, et al.
In Vivo (Athens, Greece)|January 16, 2014
The use of platelet-rich plasma gel in patients with mixed tumour undergoing superficial parotidectomy: a randomized studyMarco Scala, Paola Mereu, Francesco Spagnolo, et al.
Expert Review of Anticancer Therapy|April 25, 2020
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanomaFrancesco Spagnolo, Elena Croce, Andrea Boutros, et al.
Frontiers in Oncology|October 11, 2021
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?Enrica Teresa Tanda, Agostina Lagodin d'Amato, Giovanni Rossi, et al.
In Vivo (Athens, Greece)|November 16, 2014
Regenerative medicine for the treatment of Teno-desmic injuries of the equine. A series of 150 horses treated with platelet-derived growth factorsMarco Scala, Silvia Lenarduzzi, Francesco Spagnolo, et al.
Frontiers in Immunology|December 14, 2020
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma PatientAndrea Boutros, Chiara Schiavi, Federica Cecchi, et al.
Frontiers in Molecular Biosciences|August 28, 2020
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical ImplicationsIrene Vanni, Enrica Teresa Tanda, Bruna Dalmasso, et al.
Cancer Treatment Reviews|June 22, 2024
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanomaEdoardo De Simoni, Francesco Spagnolo, Sara Gandini, et al.
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
Oncotargets and Therapy|February 6, 2015
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategiesFrancesco Spagnolo, Paola Ghiorzo, Laura Orgiano, et al.
Frontiers in Oncology|September 13, 2021
Immunotherapy for the Treatment of Cutaneous Squamous Cell CarcinomaAndrea Boutros, Federica Cecchi, Enrica Teresa Tanda, et al.
Journal for Immunotherapy of Cancer|May 27, 2026
Immunotherapy for early-stage cutaneous squamous cell carcinomaAndrea Boutros, Yu-Ju Kuo, Alexander Maxwell Menzies, et al.
In Vivo (Athens, Greece)|January 16, 2014
The use of platelet-rich plasma gel in patients with mixed tumour undergoing superficial parotidectomy: a randomized studyMarco Scala, Paola Mereu, Francesco Spagnolo, et al.
Expert Review of Anticancer Therapy|April 25, 2020
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanomaFrancesco Spagnolo, Elena Croce, Andrea Boutros, et al.
Frontiers in Oncology|October 11, 2021
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?Enrica Teresa Tanda, Agostina Lagodin d'Amato, Giovanni Rossi, et al.
In Vivo (Athens, Greece)|November 16, 2014
Regenerative medicine for the treatment of Teno-desmic injuries of the equine. A series of 150 horses treated with platelet-derived growth factorsMarco Scala, Silvia Lenarduzzi, Francesco Spagnolo, et al.
Frontiers in Immunology|December 14, 2020
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma PatientAndrea Boutros, Chiara Schiavi, Federica Cecchi, et al.
Frontiers in Molecular Biosciences|August 28, 2020
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical ImplicationsIrene Vanni, Enrica Teresa Tanda, Bruna Dalmasso, et al.
Cancer Treatment Reviews|June 22, 2024
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanomaEdoardo De Simoni, Francesco Spagnolo, Sara Gandini, et al.
Pageof 12